SCHEMBL5136318

SCHEMBL5136318

CCCCN(Cc1ccc2c(c1)OCO2)Cc1c(-c2ccc(Cl)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.65
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
F2R P25116 4/20 0.39
TSHR P16473 2/20 0.39
GNRHR P30968 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
CASP1 P29466 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HSP90AA1 P07900 2/20 0.37
HSP90AB1 P08238 2/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651206 0.96 C5AR1 (0.68) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL5136601 0.95 C5AR1 (0.58) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL5137882 0.95 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL5137483 0.92 C5AR1 (0.67) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL5135265 0.92 C5AR1 (0.65) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL5136055 0.92 C5AR1 (0.65) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL649868 0.92 C5AR1 (0.66) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL651051 0.92 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL4767016 0.91 C5AR1 (0.75) C5AR1SMN1; SMN2LMNAL3MBTL1F2R
SCHEMBL5134900 0.90 C5AR1 (0.63) C5AR1SMN1; SMN2LMNAL3MBTL1F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed